Product Code: 978-1-68038-716-2
Infectious Disease In Vitro Diagnostics Market Growth & Trends:
The global infectious disease in vitro diagnostics market size is expected to reach USD 28.05 billion by 2030, registering a CAGR of 2.4% during the forecast period, according to a new report by Grand View Research, Inc. The rising prevalence of infectious diseases, such as tuberculosis & COVID-19, and technological advancements are projected to drive the product demand in the coming years. The rising prevalence of multi-drug resistant infections is enhancing the early diagnosis of infectious diseases. For instance, MDR infections are highly common in ICU patients, as per the Microbial Drug Resistance Journal in 2021, the prevalence of MDR infections in critically ill SARS-CoV-2 patients ranged between14% and 50%.
The delay in diagnosis and treatment with antibiotics before infection diagnosis is further escalating the prevalence of drug resistant-bacteria, creating a lucrative opportunity for industry growth. The industry is witnessing a significant number of product launches to meet the demands of consumers. For instance, in May 2022, BD introduced its automated diagnostic platform for infectious diseases in the U.S. The system allows the loading of 1700 specimens and the need for specimen sorting is also eliminated, thereby, reducing errors. Products offered by various competitors have been strategically priced to increase competitive rivalry.
However, complexity in buying behavior increases prominently when consumers have to choose between PoC and lab-based tests owing to differences in sensitivity and beliefs. The industry is oligopolistic with companies, such as Hoffmann-La Roche Ltd., Alere, bioMerieux, and BD, holding the majority of the share collectively. The global industry is price-sensitive, creating rigorous competition among players in terms of manufacturing cost-effective and efficient products. Competitive rivalry is estimated to increase during the forecast period owing to the expected launch of novel biomarker kits. Competitors are adopting key strategies, such as product launches and organizing awareness programs, to gain higher market shares.
Infectious Disease In Vitro Diagnostics Market Report Highlights:
- The reagents product segment held the largest revenue share in 2023 owing to its high-volume usage in testing
- The molecular diagnostics segment held the largest share in 2023 owing to an increased number of product launches in the segment and increased adoption due to its high accuracy
- By application, the COVID-19 segment dominated the industry in 2023 due to the high expenditure on testing, to reduce the spread of the virus
- The central laboratories segment held the highest revenue share in 2023 due to the higher accuracy of laboratory-based tests, which makes them more reliable as compared to PoC and home tests, giving these tests a competitive edge over the other two segments
- North America dominated the global industry in 2023 due to its favorable regulatory framework, focus on preventive & early testing, and the higher adoption rate of novel diagnostics in this region.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.2.1. Product
- 1.2.2. Technology
- 1.2.3. Application
- 1.2.4. Test Location
- 1.3. Regional Scope
- 1.4. Estimates and Forecast Timeline
- 1.5. Research Methodology
- 1.6. Information Procurement
- 1.6.1. Purchased Database
- 1.6.2. GVR's Internal Database
- 1.7. Details of primary research
- 1.8. Market Formulation & Validation
- 1.9. Model Details
- 1.9.1. Commodity flow analysis (Model 1)
- 1.9.1.1. Approach 1: Commodity flow approach
- 1.9.2. Volume price analysis (Model 2)
- 1.9.2.1. Approach 2: Volume price analysis
- 1.10. Research Scope and Assumptions
- 1.10.1. List of Secondary Sources
- 1.10.2. List of Primary Sources
- 1.10.3. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
Chapter 3. Infectious Disease In Vitro Diagnostics Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Drivers Analysis
- 3.2.1.1. Growing geriatric population
- 3.2.1.2. Technological advancements
- 3.2.1.3. High demand for PoC facilities
- 3.2.1.4. Increasing prevalence of infectious diseases
- 3.2.1.5. External funding for R&D activities
- 3.2.2. Market Restraints Analysis
- 3.2.2.1. High prices of IVD tests
- 3.3. Infectious Disease In Vitro Diagnostics Market Analysis Tools
- 3.3.1. Porter's Analysis
- 3.3.1.1. Bargaining power of the suppliers
- 3.3.1.2. Bargaining power of the buyers
- 3.3.1.3. Threats of substitution
- 3.3.1.4. Threats from new entrants
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Economic and Social landscape
- 3.3.2.3. Technological landscape
- 3.3.2.4. Legal landscape
Chapter 4. Infectious Disease In Vitro Diagnostics Market: Product Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Infectious Disease In Vitro Diagnostics Market: Product Movement Analysis, 2023 & 2030 (USD Billion)
- 4.3. Instruments
- 4.3.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 4.4. Reagents
- 4.4.1. Reagents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 4.5. Software
- 4.5.1. Software Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
Chapter 5. Infectious Disease In Vitro Diagnostics Market: Technology Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Infectious Disease In Vitro Diagnostics Market: Technology Movement Analysis, 2023 & 2030 (USD Billion)
- 5.3. Immunoassay
- 5.3.1. Immunoassay Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 5.4. Molecular Diagnostics
- 5.4.1. Molecular Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 5.5. Microbiology
- 5.5.1. Microbiology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 5.6. Others
- 5.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
Chapter 6. Infectious Disease In Vitro Diagnostics Market: Application Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Infectious Disease In Vitro Diagnostics Market: Application Movement Analysis, 2023 & 2030 (USD Billion)
- 6.3. MRSA
- 6.3.1. MRSA Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 6.4. Streptococcus
- 6.4.1. Streptococcus Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 6.5. Clostridium difficile
- 6.5.1. Clostridium difficile Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 6.6. VRE
- 6.6.1. VRE Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 6.7. CRE
- 6.7.1. CRE Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 6.8. Respiratory Virus
- 6.8.1. Respiratory Virus Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 6.9. Candida
- 6.9.1. Candida Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 6.10. TB and drug-resistant TB
- 6.10.1. TB and Drug-resistant TB Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 6.11. Gastro-intestinal panel testing
- 6.11.1. Gastro-intestinal Panel Testing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 6.12. Chlamydia
- 6.12.1. Chlamydia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 6.13. Gonorrhea
- 6.13.1. Gonorrhea Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 6.14. HPV
- 6.14.1. HPV Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 6.15. HIV
- 6.15.1. HIV Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 6.16. Hepatitis C
- 6.16.1. Hepatitis C Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 6.17. Hepatitis B
- 6.17.1. Hepatitis B Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 6.18. COVID-19
- 6.18.1. COVID-19 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 6.19. Other Infectious Diseases
- 6.19.1. Others Market Revenue Estimates and Forecasts, 2018 -
Chapter 7. Infectious Disease In Vitro Diagnostics Market: Test Location Estimates & Trend Analysis
- 7.1. Segment Dashboard
- 7.2. Infectious Disease In Vitro Diagnostics Market: Test Location Movement Analysis, 2023 & 2030 (USD Billion)
- 7.3. Point of Care
- 7.3.1. Point of Care Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.4. Central Laboratories
- 7.4.1. Central Laboratories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.5. Others
- 7.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
Chapter 8. Infectious Disease In Vitro Diagnostics Market: Regional Estimates & Trend Analysis
- 8.1. Infectious Disease In Vitro Diagnostics Market Share, By Region, 2023 & 2030 (USD Billion)
- 8.2. North America
- 8.2.1. North America Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 8.2.2. U.S.
- 8.2.2.1. Key Country Dynamics
- 8.2.2.2. Regulatory Landscape/Reimbursement Scenario
- 8.2.2.3. Competitive Insights
- 8.2.2.4. U.S. Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 8.2.3. Canada
- 8.2.3.1. Key Country Dynamics
- 8.2.3.2. Regulatory Landscape/Reimbursement Scenario
- 8.2.3.3. Competitive Insights
- 8.2.3.4. Canada Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 8.3. Europe
- 8.3.1. Europe Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 8.3.2. U.K.
- 8.3.2.1. Key Country Dynamics
- 8.3.2.2. Regulatory Landscape/Reimbursement Scenario
- 8.3.2.3. Competitive Insights
- 8.3.2.4. U.K. Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 8.3.3. Germany
- 8.3.3.1. Key Country Dynamics
- 8.3.3.2. Regulatory Landscape/Reimbursement Scenario
- 8.3.3.3. Competitive Insights
- 8.3.3.4. Germany Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 8.3.4. France
- 8.3.4.1. Key Country Dynamics
- 8.3.4.2. Regulatory Landscape/Reimbursement Scenario
- 8.3.4.3. Competitive Insights
- 8.3.4.4. France Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 8.3.5. Italy
- 8.3.5.1. Key Country Dynamics
- 8.3.5.2. Regulatory Landscape/Reimbursement Scenario
- 8.3.5.3. Competitive Insights
- 8.3.5.4. Italy Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 8.3.6. Spain
- 8.3.6.1. Key Country Dynamics
- 8.3.6.2. Regulatory Landscape/Reimbursement Scenario
- 8.3.6.3. Competitive Insights
- 8.3.6.4. Spain Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 8.3.7. Sweden
- 8.3.7.1. Key Country Dynamics
- 8.3.7.2. Regulatory Landscape/Reimbursement Scenario
- 8.3.7.3. Competitive Insights
- 8.3.7.4. Sweden Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 8.3.8. Denmark
- 8.3.8.1. Key Country Dynamics
- 8.3.8.2. Regulatory Landscape/Reimbursement Scenario
- 8.3.8.3. Competitive Insights
- 8.3.8.4. Denmark Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 8.3.9. Norway
- 8.3.9.1. Key Country Dynamics
- 8.3.9.2. Regulatory Landscape/Reimbursement Scenario
- 8.3.9.3. Competitive Insights
- 8.3.9.4. Norway Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 8.4. Asia Pacific
- 8.4.1. Asia Pacific Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 8.4.2. China
- 8.4.2.1. Key Country Dynamics
- 8.4.2.2. Regulatory Landscape/Reimbursement Scenario
- 8.4.2.3. Competitive Insights
- 8.4.2.4. China Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 8.4.3. Japan
- 8.4.3.1. Key Country Dynamics
- 8.4.3.2. Regulatory Landscape/Reimbursement Scenario
- 8.4.3.3. Competitive Insights
- 8.4.3.4. Japan Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 8.4.4. India
- 8.4.4.1. Key Country Dynamics
- 8.4.4.2. Regulatory Landscape/Reimbursement Scenario
- 8.4.4.3. Competitive Insights
- 8.4.4.4. India Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 8.4.5. South Korea
- 8.4.5.1. Key Country Dynamics
- 8.4.5.2. Regulatory Landscape/Reimbursement Scenario
- 8.4.5.3. Competitive Insights
- 8.4.5.4. South Korea Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 8.4.6. Australia
- 8.4.6.1. Key Country Dynamics
- 8.4.6.2. Regulatory Landscape/Reimbursement Scenario
- 8.4.6.3. Competitive Insights
- 8.4.6.4. Australia Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 8.4.7. Thailand
- 8.4.7.1. Key Country Dynamics
- 8.4.7.2. Regulatory Landscape/Reimbursement Scenario
- 8.4.7.3. Competitive Insights
- 8.4.7.4. Thailand Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 8.5. Latin America
- 8.5.1. Latin America Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 8.5.2. Brazil
- 8.5.2.1. Key Country Dynamics
- 8.5.2.2. Regulatory Landscape/Reimbursement Scenario
- 8.5.2.3. Competitive Insights
- 8.5.2.4. Brazil Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 8.5.3. Mexico
- 8.5.3.1. Key Country Dynamics
- 8.5.3.2. Regulatory Landscape/Reimbursement Scenario
- 8.5.3.3. Competitive Insights
- 8.5.3.4. Mexico Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 8.5.4. Argentina
- 8.5.4.1. Key Country Dynamics
- 8.5.4.2. Regulatory Landscape/Reimbursement Scenario
- 8.5.4.3. Competitive Insights
- 8.5.4.4. Argentina Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 8.6. Middle East and Africa
- 8.6.1. Middle East and Africa Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 8.6.2. Saudi Arabia
- 8.6.2.1. Key Country Dynamics
- 8.6.2.2. Regulatory Landscape/Reimbursement Scenario
- 8.6.2.3. Competitive Insights
- 8.6.2.4. Saudi Arabia Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 8.6.3. UAE
- 8.6.3.1. Key Country Dynamics
- 8.6.3.2. Regulatory Landscape/Reimbursement Scenario
- 8.6.3.3. Competitive Insights
- 8.6.3.4. UAE Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 8.6.4. South Africa
- 8.6.4.1. Key Country Dynamics
- 8.6.4.2. Regulatory Landscape/Reimbursement Scenario
- 8.6.4.3. Competitive Insights
- 8.6.4.4. South Africa Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 8.6.5. Kuwait
- 8.6.5.1. Key Country Dynamics
- 8.6.5.2. Regulatory Landscape/Reimbursement Scenario
- 8.6.5.3. Competitive Insights
- 8.6.5.4. Kuwait Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
Chapter 9. Competitive Landscape
- 9.1. Recent Developments & Impact Analysis by Key Market Participants
- 9.2. Company Categorization
- 9.3. Company Market Share Analysis
- 9.4. Company Heat Map Analysis
- 9.5. Strategy Mapping
- 9.5.1. Expansion
- 9.5.2. Mergers & Acquisition
- 9.5.3. Partnerships & Collaborations
- 9.5.4. New Product Launches
- 9.5.5. Research And Development
- 9.6. Company Profiles
- 9.6.1. QIAGEN
- 9.6.1.1. Participant's Overview
- 9.6.1.2. Financial Performance
- 9.6.1.3. Product Benchmarking
- 9.6.1.4. Recent Developments
- 9.6.2. BD
- 9.6.2.1. Participant's Overview
- 9.6.2.2. Financial Performance
- 9.6.2.3. Product Benchmarking
- 9.6.2.4. Recent Developments
- 9.6.3. bioMerieux SA
- 9.6.3.1. Participant's Overview
- 9.6.3.2. Financial Performance
- 9.6.3.3. Product Benchmarking
- 9.6.3.4. Recent Developments
- 9.6.4. F. Hoffmann-La Roche, Ltd.
- 9.6.4.1. Participant's Overview
- 9.6.4.2. Financial Performance
- 9.6.4.3. Product Benchmarking
- 9.6.4.4. Recent Developments
- 9.6.5. Hologic, Inc. (Gen Probe)
- 9.6.5.1. Participant's Overview
- 9.6.5.2. Financial Performance
- 9.6.5.3. Product Benchmarking
- 9.6.5.4. Recent Developments
- 9.6.6. Abbott
- 9.6.6.1. Participant's Overview
- 9.6.6.2. Financial Performance
- 9.6.6.3. Product Benchmarking
- 9.6.6.4. Recent Developments
- 9.6.7. Quidel Corporation
- 9.6.7.1. Participant's Overview
- 9.6.7.2. Financial Performance
- 9.6.7.3. Product Benchmarking
- 9.6.7.4. Recent Developments
- 9.6.8. Siemens Healthineers AG
- 9.6.8.1. Participant's Overview
- 9.6.8.2. Financial Performance
- 9.6.8.3. Product Benchmarking
- 9.6.8.4. Recent Developments
- 9.6.9. Bio-Rad Laboratories, Inc.
- 9.6.9.1. Participant's Overview
- 9.6.9.2. Financial Performance
- 9.6.9.3. Product Benchmarking
- 9.6.9.4. Recent Developments
- 9.6.10. Danaher
- 9.6.10.1. Participant's Overview
- 9.6.10.2. Financial Performance
- 9.6.10.3. Product Benchmarking
- 9.6.10.4. Recent Developments
- 9.6.11. OraSure Technologies, Inc.
- 9.6.11.1. Participant's Overview
- 9.6.11.2. Financial Performance
- 9.6.11.3. Product Benchmarking
- 9.6.11.4. Recent Developments